Our politicians and health technology institutions invite this comparison, and the obvious question, given that the latter consistently invokes opportunity cost to justify rejecting funding for innovative medicines. Opportunity cost is not just an economic consideration. It is a moral and ethical question when the powerful are preferenced over patients. …
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - -
Island secures USAMRIID partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News -
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News